Drug Profile
DTaP poliovirus vaccine - Sanofi Pasteur
Alternative Names: DTacP-IPV combined vaccine - Sanofi; Tetravac; TetraximLatest Information Update: 04 Apr 2022
Price :
$50
*
At a glance
- Originator Aventis Pasteur (now called sanofi pasteur)
- Developer Sanofi; Sanofi Pasteur
- Class Bacterial vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Diphtheria; Pertussis; Poliomyelitis; Tetanus
Most Recent Events
- 03 Mar 2014 Launched prior to 2014 for Diphtheria (prevention, in infants and children) in Argentina, Austria, Belgium, Finland, France, Germany, Greece, Italy, Hong Kong, Hungary, Ireland, Malaysia, Norway, Philippines, Portugal, South Africa, South Korea, Switzerland, Thailand, Turkey and the United Kingdom (IM)
- 03 Mar 2014 Launched prior to 2014 for Tetanus (prevention, in infants and children) in Argentina, Austria, Belgium, Finland, France, Germany, Greece, Italy, Hong Kong, Hungary, Ireland, Malaysia, Norway, Philippines, Portugal, South Africa, South Korea, Switzerland, Thailand, Turkey and the United Kingdom (IM)
- 03 Mar 2014 Launched prior to 2014 for Pertussis (prevention, in infants and children) in Argentina, Austria, Belgium, Finland, France, Germany, Greece, Italy, Hong Kong, Hungary, Ireland, Malaysia, Norway, Philippines, Portugal, South Africa, South Korea, Switzerland, Thailand, Turkey and the United Kingdom (IM)